Robinson Chandler reported option exercise involving 15,000 shares of Monopar Therapeutics at $14.00 for $210k on Sep 24, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Executive Officer
Chief Executive Officer
Filed Sep 28, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$210,000Shares × reported price
Shares traded
15,000Common Stock
Price per share
$14.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
128,323Direct
Trade date
Sep 24, 2026Option exercise
Filed
Sep 28, 2026, 8:47 PM ET5-day reporting delay
Accession
0001437749-26-031411Code M · Transaction 230697
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 24, 2026Option exercise14,056$0.00$0Trade 230702
Sep 24, 2026Option exercise15,000$0.00$0Trade 230703
Sep 24, 2026Option exercise14,056$30.00$421,680Trade 230696
Sep 24, 2026Sell10,450$87.15−$910,717.50Trade 230698
Sep 24, 2026Sell9,638$87.96−$847,758.48Trade 230699
Sep 24, 2026Sell8,368$88.97−$744,500.96Trade 230700
Sep 24, 2026Sell600$89.79−$53,874Trade 230701
8 transaction rows in this filing. Joint filers share the same rows.

MNPR price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MNPR · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +39%1w ago +28%1d ago +12%
Returns since7d −0.5%30d −8.3%90d180d1y

Footnotes in full

F1: This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on June 25, 2026. F2: On August 9, 2018, the reporting person was granted stock options to purchase up to 29,100 shares of common stock. Stock options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter. F3: On February 2, 2022, the reporting person was granted stock options to purchase up to 42,204 shares of common stock. Stock options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter. F4: Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.54 to $87.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.54 to $88.53, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.54 to $89.51, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.56 to $89.91, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) through (8) to this Form 4.